Literature DB >> 29296788

MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.

Silvia Maifrede1, Esteban Martinez2, Margaret Nieborowska-Skorska1, Daniela Di Marcantonio2, Michael Hulse3, Bac Viet Le1,4, Huaqing Zhao5, Katarzyna Piwocka4, Italo Tempera3, Stephen M Sykes2, Tomasz Skorski1,2.   

Abstract

PARP1 is required for the maintenance of MLL-AF9 leukemias.PARP1 inhibitors enhance the therapeutic effect of cytotoxic drugs against MLL-AF9 leukemias.

Entities:  

Year:  2017        PMID： 29296788      PMCID： PMC5728460          DOI： 10.1182/bloodadvances.2017006247

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  28 in total

Review 1.  Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.

Authors:  Rajesh C Rao; Yali Dou
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

Review 2.  DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.

Authors:  Maria Teresa Esposito; Chi Wai Eric So
Journal:  Chromosoma       Date:  2014-08-12       Impact factor: 4.316

3.  Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

Authors:  Margaret Nieborowska-Skorska; Piotr K Kopinski; Regina Ray; Grazyna Hoser; Danielle Ngaba; Sylwia Flis; Kimberly Cramer; Mamatha M Reddy; Mateusz Koptyra; Tyrone Penserga; Eliza Glodkowska-Mrowka; Elisabeth Bolton; Tessa L Holyoake; Connie J Eaves; Sabine Cerny-Reiterer; Peter Valent; Andreas Hochhaus; Timothy P Hughes; Heiko van der Kuip; Martin Sattler; Wieslaw Wiktor-Jedrzejczak; Christine Richardson; Adrienne Dorrance; Tomasz Stoklosa; David A Williams; Tomasz Skorski
Journal:  Blood       Date:  2012-03-12       Impact factor: 22.113

Review 4.  Oncogenic tyrosine kinases and the DNA-damage response.

Authors:  Tomasz Skorski
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

5.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

6.  AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.

Authors:  Mark Wunderlich; Benjamin Mizukawa; Fu-Sheng Chou; Christina Sexton; Mahesh Shrestha; Yogen Saunthararajah; James C Mulloy
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

7.  Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells.

Authors:  Andrea Viale; Francesca De Franco; Annette Orleth; Valeria Cambiaghi; Virginia Giuliani; Daniela Bossi; Chiara Ronchini; Simona Ronzoni; Ivan Muradore; Silvia Monestiroli; Alberto Gobbi; Myriam Alcalay; Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nature       Date:  2009-01-01       Impact factor: 49.962

8.  MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.

Authors:  Helge Gad; Tobias Koolmeister; Ann-Sofie Jemth; Saeed Eshtad; Sylvain A Jacques; Cecilia E Ström; Linda M Svensson; Niklas Schultz; Thomas Lundbäck; Berglind Osk Einarsdottir; Aljona Saleh; Camilla Göktürk; Pawel Baranczewski; Richard Svensson; Ronnie P-A Berntsson; Robert Gustafsson; Kia Strömberg; Kumar Sanjiv; Marie-Caroline Jacques-Cordonnier; Matthieu Desroses; Anna-Lena Gustavsson; Roger Olofsson; Fredrik Johansson; Evert J Homan; Olga Loseva; Lars Bräutigam; Lars Johansson; Andreas Höglund; Anna Hagenkort; Therese Pham; Mikael Altun; Fabienne Z Gaugaz; Svante Vikingsson; Bastiaan Evers; Martin Henriksson; Karl S A Vallin; Olov A Wallner; Lars G J Hammarström; Elisee Wiita; Ingrid Almlöf; Christina Kalderén; Hanna Axelsson; Tatjana Djureinovic; Jordi Carreras Puigvert; Maria Häggblad; Fredrik Jeppsson; Ulf Martens; Cecilia Lundin; Bo Lundgren; Ingrid Granelli; Annika Jenmalm Jensen; Per Artursson; Jonas A Nilsson; Pål Stenmark; Martin Scobie; Ulrika Warpman Berglund; Thomas Helleday
Journal:  Nature       Date:  2014-04-02       Impact factor: 49.962

9.  Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.

Authors:  Maria Teresa Esposito; Lu Zhao; Tsz Kan Fung; Jayant K Rane; Amanda Wilson; Nadine Martin; Jesus Gil; Anskar Y Leung; Alan Ashworth; Chi Wai Eric So
Journal:  Nat Med       Date:  2015-11-23       Impact factor: 53.440

10.  Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.

Authors:  Kilian V M Huber; Eidarus Salah; Branka Radic; Manuela Gridling; Jonathan M Elkins; Alexey Stukalov; Ann-Sofie Jemth; Camilla Göktürk; Kumar Sanjiv; Kia Strömberg; Therese Pham; Ulrika Warpman Berglund; Jacques Colinge; Keiryn L Bennett; Joanna I Loizou; Thomas Helleday; Stefan Knapp; Giulio Superti-Furga
Journal:  Nature       Date:  2014-04-02       Impact factor: 49.962
View more
  12 in total

1.  Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Authors:  Silvia Maifrede; Margaret Nieborowska-Skorska; Katherine Sullivan-Reed; Yashodhara Dasgupta; Paulina Podszywalow-Bartnicka; Bac Viet Le; Martyna Solecka; Zhaorui Lian; Elizaveta A Belyaeva; Alina Nersesyan; Marcin M Machnicki; Monika Toma; Nicolas Chatain; Malgorzata Rydzanicz; Huaqing Zhao; Jaroslav Jelinek; Katarzyna Piwocka; Tomasz Sliwinski; Tomasz Stoklosa; Rafal Ploski; Thomas Fischer; Stephen M Sykes; Steffen Koschmieder; Lars Bullinger; Peter Valent; Mariusz A Wasik; Jian Huang; Tomasz Skorski
Journal:  Blood       Date:  2018-05-21       Impact factor: 22.113

Review 2.  Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies.

Authors:  Sara Zarnegar-Lumley; Kenneth J Caldwell; Jeffrey E Rubnitz
Journal:  Leukemia       Date:  2022-06-06       Impact factor: 12.883

Review 3.  Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.

Authors:  Daniil E Shabashvili; Yang Feng; Prabhjot Kaur; Kartika Venugopal; Olga A Guryanova
Journal:  Exp Hematol       Date:  2022-03-16       Impact factor: 3.249

4.  Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.

Authors:  Sana D Karam; Krishna Reddy; Patrick J Blatchford; Tim Waxweiler; Alicia M DeLouize; Ayman Oweida; Hilary Somerset; Carrie Marshall; Christian Young; Kurtis D Davies; Madeleine Kane; Aik Choo Tan; Xiao Jing Wang; Antonio Jimeno; Dara L Aisner; Daniel W Bowles; David Raben
Journal:  Clin Cancer Res       Date:  2018-07-03       Impact factor: 12.531

Review 5.  Targeting DNA Repair and Chromatin Crosstalk in Cancer Therapy.

Authors:  Danielle P Johnson; Mahesh B Chandrasekharan; Marie Dutreix; Srividya Bhaskara
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.575

Review 6.  PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.

Authors:  Claire Fritz; Scott M Portwood; Amanda Przespolewski; Eunice S Wang
Journal:  Blood Rev       Date:  2020-05-07       Impact factor: 10.626

7.  Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.

Authors:  Katherine Sullivan-Reed; Elisabeth Bolton-Gillespie; Yashodhara Dasgupta; Samantha Langer; Micheal Siciliano; Margaret Nieborowska-Skorska; Kritika Hanamshet; Elizaveta A Belyaeva; Andrea J Bernhardy; Jaewong Lee; Morgan Moore; Huaqing Zhao; Peter Valent; Ksenia Matlawska-Wasowska; Markus Müschen; Smita Bhatia; Ravi Bhatia; Neil Johnson; Mariusz A Wasik; Alexander V Mazin; Tomasz Skorski
Journal:  Cell Rep       Date:  2018-06-12       Impact factor: 9.423

8.  Idarubicin-loaded methoxy poly(ethylene glycol)-b-poly(l-lactide-co-glycolide) nanoparticles for enhancing cellular uptake and promoting antileukemia activity.

Authors:  Bin Liang; Na Li; Shuofei Zhang; Aihua Qi; Jianhua Feng; Weiwei Jing; Changcan Shi; Zhaipu Ma; Shenmeng Gao
Journal:  Int J Nanomedicine       Date:  2019-01-11

Review 9.  PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Christina-Nefeli Kontandreopoulou; Panagiotis T Diamantopoulos; Despina Tiblalexi; Nefeli Giannakopoulou; Nora-Athina Viniou
Journal:  Blood Adv       Date:  2021-11-23

Review 10.  PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.

Authors:  Clifford M Csizmar; Antoine N Saliba; Elizabeth M Swisher; Scott H Kaufmann
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.